Eli Lilly and Company
LLY
$734.57
-$16.88-2.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -37.43% | 354.48% | -67.30% | 32.28% | 2.43% |
| Total Depreciation and Amortization | -4.54% | 3.86% | 12.64% | 3.44% | 3.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,022.77% | -108.57% | 542.67% | -288.56% | -3.25% |
| Change in Net Operating Assets | -51.21% | -22,603.06% | 99.30% | 20.11% | 44.80% |
| Cash from Operations | -32.67% | -33.35% | 153.16% | 25.75% | 473.84% |
| Capital Expenditure | -0.90% | -10.76% | -10.28% | -24.18% | 7.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -334.11% | 84.01% | -10,029.77% | 86.30% | 76.37% |
| Cash from Investing | -74.55% | 52.04% | -82.14% | -86.71% | 59.73% |
| Total Debt Issued | -- | -100.00% | -- | -100.00% | 40.44% |
| Total Debt Repaid | -160.77% | 198.48% | -212.92% | 152.56% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 41.57% | -360.41% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.24% | 0.19% | 0.16% | -0.27% | -14.84% |
| Other Financing Activities | -1,408.35% | 3.81% | -491.25% | 97.95% | -1,133.54% |
| Cash from Financing | 712.11% | -206.67% | -86.42% | 599.68% | -108.78% |
| Foreign Exchange rate Adjustments | 130.78% | -288.85% | 480.70% | -67.89% | -127.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.06% | -169.19% | -80.95% | 313.00% | -181.86% |